Drugmaker Eli Lilly says experimental Alzheimer’s drug remternetug is part of the next generation of anti-amyloids. The approval of the controversial anti-amyloid drug Aduhelm…
A second patient has died of brain bleeds — an anti-amyloid side effect — during the clinical trial extension of Eisai’s Alzheimer’s treatment lecanemab…
Eisai’s investigational Alzheimer’s drug lecanemab appeared to erase amyloid plaques in 4/5 of trial participants and slow cognitive decline for people with early-stage Alzheimer’s…
“It’s Time for More Time” With the #MoreTime campaign, the Alzheimer’s Association has gone all in on aducanumab, the controversial new Alzheimer’s drug produced…
The long search for a drug to slow the decline of Alzheimer’s may have reached a turning point. Pharmaceutical companies Biogen and Eisai have…
After years of failure, including some pharmaceutical companies calling off Alzheimer’s research altogether, Biogen offers a glimmer of hope: New data from a Phase…